At the end of 2020 and early 2021, SUPA71 completed a qualitative baseline study to assess information for the RAI2E COMBAT Trial Study in Thailand for the University of California San Francisco(UCSF). The RAI2E COMBAT Trial Study was recently launched to evaluate the effectiveness and feasibility of a reactive focal mass drug administration (rfMDA) strategy targeting the high-risk forest workers from P. vivax and falciparuminfection. Results of the studywould have direct implications for the continued roll-out of community-led foci management, providing practical guidance that other malaria programs can utilize. The data was collected among to collect information using key informant interviews (KIIs) and Focus Group Discussions (FGDs) in Tak and Ubon Ratchathani provinces. The research involved respondents who were purposively selected which included staff and officers of Provincial Health Offices (PHOs), District Health Offices (DHOs), Health Promoting Hospital (HPHs), Community Health Service Center (CHSV), Health Centers (HCs), Vector-Borne Disease Centers (VBDCs), Vector-Borne Disease Units (VBDUs), local Village Health Volunteers (VHVs), Village Malaria Workers (VMWs), and High-Risk Populations (HRPs). SUPA71 would like to thank you all the respondents of this study. We received informative information for further implementation.